Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. BLTE
stocks logo

BLTE

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.390
+25.81%
--
--
-0.393
+40.18%
--
--
-0.050
-84.38%
Estimates Revision
The market is revising No Change the revenue expectations for Belite Bio, Inc (BLTE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 9.54%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+53.66%
In Past 3 Month
Stock Price
Go Up
up Image
+9.54%
In Past 3 Month
5 Analyst Rating
up Image0
Wall Street analysts forecast BLTE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 96.67 USD with a low forecast of 80.00 USD and a high forecast of 110.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 59.260
sliders
Low
80.00
Averages
96.67
High
110.00
up Image0
Current: 59.260
sliders
Low
80.00
Averages
96.67
High
110.00
Benchmark
Bruce Jackson
Strong Buy
Reiterates
$80
2025-03-26
Reason
Benchmark
Bruce Jackson
Price Target
$80
2025-03-26
Reiterates
Strong Buy
Reason
Benchmark raised the firm's price target on Belite Bio to $80 from $79 and keeps a Buy rating on the shares. In February, Belite received a positive report from an interim data analysis of the Phase 3 DRAGON trial and a DSMB recommendation to seek accelerated regulatory approval, notes the analyst, who calls out completion of the DRAGON II study around mid-year and completion of the DRAGON study by year-end 2025 as the next major catalysts for the shares.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$100
2025-03-18
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$100
2025-03-18
Reiterates
Strong Buy
Reason
Cantor Fitzgerald
Jennifer Kim
Buy
Reiterates
n/a
2025-03-18
Reason
Cantor Fitzgerald
Jennifer Kim
Price Target
n/a
2025-03-18
Reiterates
Buy
Reason
Benchmark
Bruce Jackson
Strong Buy
Maintains
$57 → $79
2025-01-21
Reason
Benchmark
Bruce Jackson
Price Target
$57 → $79
2025-01-21
Maintains
Strong Buy
Reason
Benchmark raised the firm's price target on Belite Bio to $79 from $57 and keeps a Buy rating on the shares. After speaking to management at a conference last week, the firm revisited its pricing assumptions for Tinlarebant in the treatment of Stargardt disease type 1 and now assumes an average price of $50,000, the analyst tells investors.
Maxim Group
Jason McCarthy
Strong Buy
Maintains
$60 → $110
2024-11-15
Reason
Maxim Group
Jason McCarthy
Price Target
$60 → $110
2024-11-15
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$60 → $100
2024-11-13
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$60 → $100
2024-11-13
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Belite Bio Inc (BLTE.O) is -44.96, compared to its 5-year average forward P/E of -34.49. For a more detailed relative valuation and DCF analysis to assess Belite Bio Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-34.49
Current PE
-44.96
Overvalued PE
-24.01
Undervalued PE
-44.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
13.72
Current PS
193.53
Overvalued PS
63.87
Undervalued PS
-36.42

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BLTE News & Events

Events Timeline

(ET)
2025-07-02
05:11:57
Belite Bio completes enrollment in PHOENIX trial
select
2025-05-21 (ET)
2025-05-21
05:23:41
Belite Bio announces Breakthrough Therapy Designation for Tinlarebant from FDA
select
2025-05-14 (ET)
2025-05-14
05:24:39
Belite Bio reports Q1 EPS (27c), consensus (37c)
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
07-03Benzinga
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $100 Price Target
  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.

Preview
9.0
07-02Newsfilter
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
  • Enrollment Completion: Belite Bio has completed enrollment for the PHOENIX trial, a Phase 3 study evaluating the safety and efficacy of Tinlarebant in treating geographic atrophy associated with dry age-related macular degeneration, across multiple countries including the US, UK, and China.

  • Significance of Tinlarebant: Tinlarebant is an oral therapy aimed at addressing significant unmet medical needs in patients with geographic atrophy and Stargardt disease type 1, with no currently approved oral treatments available for these conditions.

Preview
2.0
06-07NASDAQ.COM
BLTE Crosses Below Key Moving Average Level
  • Stock Performance Overview: BLTE's stock has a 52-week low of $43.70 and a high of $86.53, with the latest trade recorded at $59.68.

  • Market Analysis Note: The article mentions other stocks that have recently fallen below their 200-day moving average, indicating potential market trends.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Belite Bio Inc (BLTE) stock price today?

The current price of BLTE is 59.26 USD — it has increased 1.07 % in the last trading day.

arrow icon

What is Belite Bio Inc (BLTE)'s business?

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

arrow icon

What is the price predicton of BLTE Stock?

Wall Street analysts forecast BLTE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 96.67 USD with a low forecast of 80.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Belite Bio Inc (BLTE)'s revenue for the last quarter?

Belite Bio Inc revenue for the last quarter amounts to -15.52M USD, increased 86.32 % YoY.

arrow icon

What is Belite Bio Inc (BLTE)'s earnings per share (EPS) for the last quarter?

Belite Bio Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Belite Bio Inc (BLTE)'s fundamentals?

The market is revising No Change the revenue expectations for Belite Bio, Inc (BLTE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 9.54%.
arrow icon

How many employees does Belite Bio Inc (BLTE). have?

Belite Bio Inc (BLTE) has 25 emplpoyees as of July 08 2025.

arrow icon

What is Belite Bio Inc (BLTE) market cap?

Today BLTE has the market capitalization of 1.91B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free